{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:05:49Z","timestamp":1784142349092,"version":"3.55.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":174,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Coatomer subunit \u03b1 (COPA) syndrome is a rare, autosomal dominant inborn error of immunity driven by dysregulated type I interferon signalling. It typically presents in early childhood with interstitial lung disease, arthritis, and systemic inflammation. Current treatments are largely extrapolated from adult protocols, and disease management remains challenging. Recent evidence suggests that Janus kinase inhibitors (JAKi), which block interferon signalling, may offer a targeted therapeutic approach. We report on two paediatric patients with genetically confirmed COPA syndrome who demonstrated sustained clinical improvement following the initiation of baricitinib, a JAKi. Both cases exhibited early onset interstitial lung disease and systemic inflammation. Genetic testing identified pathogenic variants in the COPA gene. Conventional immunosuppressants provided only partial and temporary relief with disease flares occurring when immunosuppression was tapered. Baricitinib was initiated, and both patients showed a rapid clinical response, improved pulmonary function, reduced systemic inflammation, lung parenchymal radiographic stabilisation, and improvement of interstitial lung disease symptoms. Baricitinib was well tolerated overall and enabled the tapering and discontinuation of corticosteroids and other immunosuppressants. These cases align with the limited existing literature showing the efficacy of JAKi in COPA syndrome and further support the role of precision medicine targeting type I interferonopathies. While long-term safety data remain limited, early findings suggest that JAK inhibition represents a promising therapeutic strategy in COPA syndrome. Careful monitoring for viral reactivation and infection is essential. Larger studies and longer follow-up are needed to validate these results and to optimise the management of this complex paediatric autoimmune disease.<\/jats:p>","DOI":"10.1093\/mrcr\/rxag052","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:54:45Z","timestamp":1782302085000},"source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib in two paediatric patients with coatomer subunit alpha (COPA) syndrome: A case series and literature review"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-5192","authenticated-orcid":false,"given":"Enrique G","family":"Villarreal","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto ,","place":["Canada"]},{"name":"Division of Respiratory Medicine, The Hospital for Sick Children , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-7015","authenticated-orcid":false,"given":"Dilan","family":"Dissanayake","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto ,","place":["Canada"]},{"name":"Division of Rheumatology, The Hospital for Sick Children , Toronto ,","place":["Canada"]},{"name":"Cell and Systems Biology Program, SickKids Research Institute , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6907-5148","authenticated-orcid":false,"given":"Ronald M","family":"Laxer","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto ,","place":["Canada"]},{"name":"Division of Rheumatology, The Hospital for Sick Children , Toronto ,","place":["Canada"]},{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-5425","authenticated-orcid":false,"given":"Kenneth W","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Cell and Systems Biology, University of Toronto , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0155-7377","authenticated-orcid":false,"given":"Fiona","family":"Kritzinger","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto ,","place":["Canada"]},{"name":"Division of Respiratory Medicine, The Hospital for Sick Children , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2026071514462790400_ref1","doi-asserted-by":"publisher","first-page":"105070","DOI":"10.1016\/J.JBSPIN.2020.09.002","article-title":"COPA syndrome, 5 years after: where are we?","volume":"88","author":"Fr\u00e9mond","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2026071514462790400_ref2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.rdc.2023.06.005","article-title":"COPA syndrome from diagnosis to treatment: a clinician\u2019s guide","volume":"49","author":"Simchoni","year":"2023","journal-title":"Rheum Dis Clin N Am"},{"key":"2026071514462790400_ref3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ng.3279","article-title":"COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis","volume":"47","author":"Watkin","year":"2015","journal-title":"Nat Genet"},{"key":"2026071514462790400_ref4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jaci.2021.07.028","article-title":"JAK inhibition in the type I interferonopathies","volume":"148","author":"Crow","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026071514462790400_ref5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ard.2025.09.013","article-title":"Insights from a novel monogenic autoinflammatory disease: overview of a multicentric European cohort of 38 patients with COPA syndrome","volume":"85","author":"David","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026071514462790400_ref6","doi-asserted-by":"publisher","first-page":"e27423","DOI":"10.1002\/ppul.27423","article-title":"Significant reduction of lung disease on baricitinib therapy in a patient with COPA syndrome","volume":"60","author":"Zuliani","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026071514462790400_ref7","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.5152\/EURJRHEUM.2019.18177","article-title":"Baricitinib in therapy of COPA syndrome in a 15-year-old girl","volume":"7","author":"Krutzke","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"2026071514462790400_ref8","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jaip.2024.05.017","article-title":"Baricitinib treatment in children with COPA syndrome","volume":"12","author":"Matucci-Cerinic","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026071514462790400_ref9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s12887-022-03716-1","article-title":"A toddler with an unusually severe polyarticular arthritis and a lung involvement: a case report","volume":"22","author":"Basile","year":"2022","journal-title":"BMC Pediatr"},{"key":"2026071514462790400_ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21207767","article-title":"Biological and clinical changes in a pediatric series treated with off-label jak inhibitors","volume":"21","author":"Pin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026071514462790400_ref11","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/art.41790","article-title":"Augmentation of stimulator of interferon genes\u2013induced type I interferon production in COPA syndrome","volume":"73","author":"Kato","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026071514462790400_ref12","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1002\/mgg3.2309","article-title":"COPA syndrome caused by a novel p.Arg227Cys COPA gene variant","volume":"12","author":"Zheng","year":"2024","journal-title":"Mol Genet Genomic Med"},{"key":"2026071514462790400_ref13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/thoraxjnl-2019-213892","article-title":"Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage","volume":"75","author":"Fr\u00e9mond","year":"2020","journal-title":"Thorax"},{"key":"2026071514462790400_ref14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.arbres.2024.04.005","article-title":"Arthritis, pulmonary cysts and renal insufficiency: COPA syndrome","volume":"60","author":"Balaguer Cartagena","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"2026071514462790400_ref15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"2026071514462790400_ref16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the Oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2026071514462790400_ref17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/art.42087","article-title":"The 2021 European Alliance of Associations for Rheumatology\/American College of Rheumatology Points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE\/PRAAS, SAVI, and AGS","volume":"74","author":"Cetin Gedik","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026071514462790400_ref18","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/ANNRHEUMDIS-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026071514462790400_ref19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.medmal.2012.04.011","article-title":"BK-virus infections: a literature review","volume":"42","author":"Siguier","year":"2012","journal-title":"Med Mal Infect"},{"key":"2026071514462790400_ref20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/VIM.2007.0030","article-title":"Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults","volume":"20","author":"Zhou","year":"2007","journal-title":"Viral Immunol"},{"key":"2026071514462790400_ref21","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxag052\/68605269\/rxag052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag052\/68605269\/rxag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag052\/68605269\/rxag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:46:32Z","timestamp":1784141192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxag052\/8715454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxag052","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rxag052"}}